Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8⁺ T cells.

ABSTRACT:

Background

Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer with major challenges in both prevention and therapy. Metformin, adenosine monophosphate-activated protein kinase (AMPK) activator, has been suggested to reduce the incidence of HCC when used for patients with diabetes in preclinical and clinical studies. However, the possible effects of metformin and their mechanisms of action in non-diabetic HCC have not been adequately investigated.

Methods

Fah^-/-  mice were used to construct a liver-injury-induced non-diabetic HCC model for exploring hepatocarcinogenesis and therapeutic potential of metformin. Changes in relevant tumour and biochemical indicators were measured. Bulk and single-cell RNA-sequencing analyses were performed to validate the

SUBMITTER: He W 

PROVIDER: S-EPMC10668005 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature